AAIC 2025 Abstract
SNP234, a novel potent, aggregate selective anti‐Aβ antibody, as next generation anti‐amyloid immunotherapy amicable for subcutaneous administration
Experiments in cellsInterventions
Abstract
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that represents the most common cause of dementia in aged individuals. Given the central role of Aβ aggregation in AD, therapeutic strategies have focused on targeting Aβ to promote its clearance.
